Post hoc subgroup analysis of a randomised trial in eosinophilic oesophagitis: dupilumab increased histological remission (≤6 eos/hpf) vs placebo at week 24 in all subgroups, maintained to week 52; symptom and endoscopic scores improved similarly.
Secondary analysis
Dellon et al. Clinical Trial: Dupilumab Improves Eosinophilic Oesophagitis Outcomes Versus Placebo Regardless of Comorbidities or Treatment History in a Randomised Clinical Trial